BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline
MOTS-c: The Mitochondrial-Encoded Peptide With a Favourable PCAC Vote, Emerging Human Trial Data, and a Long Road to Compounding Approval
MOTS-c received a favourable 7-5 PCAC recommendation on 23 July 2026 for inclusion on the FDA's 503A Bulks List, yet formal rulemaking remains ahead. This briefing examines MOTS-c's mitochondrial mechanism, the state of its preclinical and early clinical evidence, and what the PCAC outcome means for research procurement in the UK and US.
30 Aug 2026
Research Pipeline
Selank: The Tuftsin-Derived Heptapeptide With Russian Regulatory Approval, Modest Western Evidence, and a Changed FDA Compounding Status in 2026
Selank is a synthetic heptapeptide developed in Russia that holds domestic regulatory approval as a prescription anxiolytic and has the most substantial human clinical dataset of any nootropic-class peptide in the Western research conversation. This briefing covers its mechanism, the state of the evidence, its 2026 FDA compounding reclassification, and what that means for UK research-procurement teams.
29 Aug 2026
Research Pipeline
KPV: The Alpha-MSH Tripeptide With an 8-6 PCAC Vote, Two Decades of Preclinical Data, and No Human Clinical Trials
KPV (lysine-proline-valine) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with preclinical anti-inflammatory evidence spanning gut, skin, and innate immunity. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend it for the 503A Bulks List — but no human clinical trials have been completed, FDA staff recommended against inclusion, and formal rulemaking has yet to begin.
28 Aug 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment With an 8-6 PCAC Vote, Decades of Preclinical Data, and No Human Efficacy Trials
TB-500, the synthetic 17-amino acid fragment of thymosin beta-4, received a favourable 8-6 advisory vote from the FDA's Pharmacy Compounding Advisory Committee on 23 July 2026 — despite agency staff recommending against listing it. No controlled human efficacy trial has yet administered TB-500 directly, making the evidence gap between preclinical promise and regulatory legitimacy unusually pronounced.
26 Aug 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With a PCAC Vote, Four Decades of Russian Research, and No Western Clinical Trials
Epitalon, a synthetic tetrapeptide derived from a pineal-gland extract, received a favourable PCAC recommendation on 24 July 2026 — cleared 7-5 against FDA staff advice. Its evidence base spans four decades of Russian research, compelling in vitro and animal data, and a near-complete absence of independent Western clinical trials. This profile examines the mechanism, the literature, and what the regulatory development means for UK research procurement.
24 Aug 2026
Research Pipeline
CJC-1295 and Ipamorelin: Mechanism, Evidence Base, and Regulatory Position in 2026
CJC-1295 and ipamorelin are the two most widely researched growth hormone secretagogue peptides in research procurement. Both remain on the FDA's Category 2 list pending further review, carry a mechanistically coherent combined-use rationale, and yet lack the clinical trial depth that would support approved compounding. This briefing covers their pharmacology, the state of the evidence, and what their regulatory position means for UK research laboratories.
23 Aug 2026
Research Pipeline
BPC-157 After the PCAC Vote: What the 8-6 Decision Means, Where the Evidence Stands, and What Comes Next
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend BPC-157 for the 503A Bulk Drug Substances List — overruling its own career scientists. The vote is non-binding, formal rulemaking will take at least 12 months, and the human evidence base remains extremely thin. This briefing sets out what the decision means in practice for research procurement teams.
20 Aug 2026
Research Pipeline
Semax: The ACTH-Derived Neuropeptide With a Favourable PCAC Vote, Three Decades of Russian Clinical Use, and No Western Regulatory Approval
Semax, a synthetic heptapeptide derived from adrenocorticotropic hormone, received a favourable PCAC recommendation on 24 July 2026 for inclusion on the FDA's 503A compounding list. This briefing examines its mechanism, the evidence base from Russian clinical programmes, and its current regulatory standing in the US, UK, and EU — a picture of a compound with an unusually long clinical history but no recognised approval outside Russia and certain CIS states.
19 Aug 2026
Research Pipeline
Retatrutide: Four Phase 3 Trials Complete, BLA Filing Set for Q1 2027 — What the TRIUMPH Data Mean for the Peptide Research Landscape
Eli Lilly completed its four-trial TRIUMPH Phase 3 programme on 23 July 2026 with positive readouts from TRIUMPH-2 and TRIUMPH-3, recording up to 22.6% weight loss in high-risk cardiovascular populations. A Biologics Licence Application is now planned for Q1 2027, making retatrutide the first triple hormone receptor agonist to advance to regulatory submission.
18 Aug 2026
Research Pipeline
KPV: The Anti-Inflammatory Tripeptide With a PCAC Vote, a Compelling Preclinical Mechanism, and No Confirmed Human Trials
KPV — the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone — received a narrow 8-6 PCAC recommendation for inclusion on the FDA's 503A Bulk Drug Substances List in July 2026. Its NF-κB inhibitory mechanism is well-characterised in cell and animal models, but no controlled human trials have confirmed clinical benefit, leaving procurement teams in a familiar position: strong mechanistic rationale, thin translational evidence, and an unresolved regulatory pathway.
17 Aug 2026
Research Pipeline
MOTS-c: The Mitochondrial-Encoded Peptide With a PCAC Vote, an Active Human Trial, and an Unresolved Regulatory Path
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA that has drawn sustained research interest for its role in metabolic regulation and exercise adaptation. Following the July 2026 PCAC vote recommending it for the FDA 503A Bulks List, procurement teams should understand where the evidence base stands and what remains unresolved before any lawful compounding pathway exists.
16 Aug 2026
Research Pipeline
TB-500 and Thymosin Beta-4: Mechanism, Evidence Base, and Regulatory Position After the July 2026 PCAC Vote
TB-500 is the synthetic research peptide most associated with thymosin beta-4, a naturally occurring actin-sequestering protein with preclinical evidence across wound healing, cardiac repair, and neural tissue models. A June 2026 scoping review mapped 80 published studies, and the FDA's PCAC voted in July 2026 to recommend the compound for the 503A compounding list — a non-binding step that leaves its formal regulatory status unchanged for now.
14 Aug 2026